Editorial: Advances in Autoimmune Myasthenia Gravis

Punga, Anna Rostedt; Kusner, Linda L.; Berrih‐Aknin, Sonia; Panse, Rozen Le

doi:10.3389/fimmu.2020.01688

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myasthenia gravis is an acquired autoimmune disease with NMJ involvement mediated by pathogenic autoimmune antibodies. The occurrence and progression of MG involves a complex immune regulatory network, including multiple immune cell interactions, cytokines, and different complement activation pathways, and CD4 + T lymphocytes play an important role in the synthesis of MG pathogenic antibodies ( 16 ). Hu et al found that the imbalance of immune response mechanism, which caused by the difference in activation level of T lymphocyte subsets, plays a key role in triggering oMG and inducing gMG production ( 17 ).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Rao

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

PurposeThis study aims to discuss the function mechanism of regulatory T cells and its subsets in the pathogenic process of myasthenia gravis by contracting the activation levels of those cells in peripheral blood among healthy people, patients with ocular myasthenia gravis (oMG) and patients with generalized myasthenia gravis (gMG).MethodHealthy people, newly diagnosed oMG patients, and gMG patients were enrolled in this study. The percentage of the CD3+CD4+CD25+ Treg cells, CD3+CD4+CD25+Foxp3+ Treg cells, CD3+CD4+CD25+Foxp3hi CD45RA–aTreg cells, CD3+CD4+CD25+Foxp3loCD45RA–n-sTreg cells, and CD3+CD4+CD25+ Foxp3loCD45RA+rTreg cells in the peripheral blood were examined by flow cytometry. And then analyzed the differences of Treg cells and its subsets among the study members.ResultsThe percentage of the CD4+CD25+Treg cells in the peripheral blood of oMG patients and gMG patients were both lower than that of healthy people (p < 0.05), the percentage of patients with oMG had no distinct difference with that of patients with gMG (p = 0.475), however. Also, the percentage of CD3+CD4+CD25+Foxp3+Treg cells in the oMG and gMG patients’ group were both lower than that of healthy group. And the percentage of CD25+Foxp3+Treg cells in the peripheral blood of patients with oMG and healthy people were both higher than that of patients with gMG (p < 0.05). The percentage of rTreg in the CD3+CD4+CD25+Treg of the peripheral blood for both gMG and oMG patients’ group were lower than healthy group (p < 0.05), but there was no statistical significance between the oMG and gMG patients’ group (p = 0.232). The percentage of the aTreg cells in the CD3+CD4+CD25+Treg cells of the peripheral blood for the oMG patients was higher than that of gMG patients (p < 0.05), but both of them were lower than healthy group (p < 0.05). The percentage of n-sTreg cells in the peripheral blood descended among the gMG patients’ group, oMG patients’ group, and healthy group (p < 0.05).ConclusionThe changes in the number and function of Treg cells and its subsets can cause the impairment of negative immune regulation, which may mediate the triggering of oMG and its progression to gMG.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Rao

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…[5][6][7] The typical clinical presentation of MG includes fluctuating muscle weakness and fatigue, worsened by activity and improved with rest, which can cause respiratory distress, myasthenic crisis, and, in severe cases, be life-threatening. [8][9][10][11] Epidemiological studies have estimated the global prevalence of MG to be approximately 15 to 25 cases per 100,000 population, with an annual incidence rate of 8 to 10 cases per 1 million. [12] The disease has a bimodal incidence pattern, affecting individuals of all ages but with a higher incidence among young women and elderly men.…”

Section: Introductionmentioning

confidence: 99%

Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study

Yang

Wu²,

Han

et al. 2023

Medicine

View full text Add to dashboard Cite

The objective of this study is to utilize bibliometric and visual analysis techniques to identify hotspots and frontiers of research in myasthenia gravis (MG) and provide valuable references for future research. The Web of Science Core Collection (WoSCC) database was used to retrieve literature data related to MG research, which was then analyzed using VOSviewer 1.6.18, CiteSpace 6.1.R3, and the Online Platform for Bibliometric Analysis. The analysis revealed 6734 publications distributed across 1612 journals and contributed by as many as 24,024 authors affiliated with 4708 institutions across 107 countries/regions. The number of annual publications and citations for MG research has steadily increased over the past 2 decades, with the last 2 years alone witnessing a remarkable increase in annual publications and citations to over 600 and 17,000, respectively. In terms of productivity, the United States emerged as the top producing country, while the University of Oxford ranked first in terms of research institutions. Vincent A was identified as the top contributor in terms of publications and citations. Muscle & Nerve and Neurology ranked first in publications and citations respectively, with clinical neurology and neurosciences among the main subject categories explored. The study also identified pathogenesis, eculizumab, thymic epithelial cells, immune checkpoint inhibitors, thymectomy, MuSK antibodies, risk, diagnosis, and management as the current hot research topics in MG, while burst keywords like quality of life, immune-related adverse events (irAEs), rituximab, safety, nivolumab, cancer, and classification indicated the frontiers of MG research. This study effectively identifies the hotspots and frontiers of MG research, and offers valuable references for researchers interested in this area.

show abstract

Circ_0076490 silencing inhibits MAPK1 expression to decrease the proliferation and increase apoptosis of Jurkat cells by regulating miR-144-3p in myasthenia gravis

Ye,

Gu,

Yan

2024

Neurological Research

View full text Add to dashboard Cite

Editorial: Advances in Autoimmune Myasthenia Gravis

Cited by 4 publications

References 12 publications

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Global research hotspots and frontiers of myasthenia gravis from 2002 to 2021: A bibliometric study

Circ_0076490 silencing inhibits MAPK1 expression to decrease the proliferation and increase apoptosis of Jurkat cells by regulating miR-144-3p in myasthenia gravis

Contact Info

Product

Resources

About